Introduction Despite representing only 3% of the US population, immunocompromised (IC)
individuals account for nearly half of the COVID-19 breakthrough hospitalizations. IC …

Although COVID-19 outcomes have improved over the pandemic for patients with RA, some
experience poor acute and postacute outcomes after COVID-19. Clinicians and patients …

Background Some patients with systemic autoimmune rheumatic disease and
immunosuppression might still be at risk of severe COVID-19. The effect of outpatient SARS …

Patients with autoimmune diseases are among the susceptible groups to COVID-19
infection because of the complexity of their conditions and the side effects of the …

Objective We investigated the baseline DMARD use and post-acute sequelae of COVID-19
(PASC) risk among patients with systemic autoimmune rheumatic diseases (SARDs) …

Background Patients with systemic autoimmune rheumatic diseases using disease-
modifying antirheumatic drugs (DMARDs) might have blunted responses to COVID-19 …

Objectives: To investigate COVID-19 breakthrough infection after third mRNA vaccine dose
among patients with RA by immunomodulator drug class, and we hypothesized that CD20 …

Background Vaccination is one of the most important measures to contain the COVID-19
pandemic, especially for frail patients. VACCINATE is a multicentre prospective …

Objective To investigate risk factors and outcomes of repeat COVID-19 infections among
patients with systemic autoimmune rheumatic diseases (SARDs). Methods We performed a …

Objective To compare the effectiveness of mRNA vaccines (BNT162b2 vs mRNA-1273)
against coronavirus disease 2019 (COVID-19) infection among patients with systemic …